GlassScriptPhysician profile
Brandon Max Markus
NPI 1134440365
$5,201.07
in general payments reported to CMS, 2019-2025
26 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $90.55 · 2021: $847 · 2022: $654 · 2023: $883 · 2024: $1,067 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,326 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,326.42 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $858.75 | 2019-2025 | |
| Abbvie INC. | $826.91 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $762.89 | 2020-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $577.65 | 2020-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $261.01 | 2023-2025 | Sotyktu |
| Smith+Nephew, INC. | $258.89 | 2019-2023 | Collagenase Santyl |
| Genzyme Corporation | $255.69 | 2021-2025 | |
| Amgen INC. | $224.58 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $173.79 | 2021-2025 | Bimzelx |
| Incyte Corporation | $158.00 | 2022-2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $115.57 | 2021-2025 | Ebglyss, Taltz |
| Organon LLC | $88.00 | 2025 | Vtama |
| Dermavant Sciences, INC. | $80.82 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $79.47 | 2022-2025 | Nemluvio |
| Pfizer INC. | $75.16 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.07 | 2022-2024 | Spevigo |
| Janssen Biotech, INC. | $60.97 | 2024-2025 | Tremfya |
| Elekta, INC. | $47.16 | 2024 | Elekta Medical Linear Accelerator |
| Allergan, INC. | $41.88 | 2021-2022 | |
| Dusa Pharmaceuticals, INC. | $41.02 | 2019 | |
| Strata Skin Sciences, INC. | $37.38 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $35.73 | 2021-2023 | Valchlor |
| Biofrontera INC. | $20.08 | 2025 | |
| Verrica Pharmaceuticals INC. | $17.51 | 2024 | Ycanth |
| Arcutis Biotherapeutics, INC. | $16.45 | 2023 | |
| Boston Scientific Corporation | $15.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Markus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.